GlassScriptPhysician profile
David N Rubin
NPI 1710097050
$1,517.18
in general payments reported to CMS, 2019-2025
19 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $191 · 2022: $66.75 · 2023: $93.01 · 2024: $119 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.30 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.97 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $144.76 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $135.84 | 2019-2022 | |
| Pfizer INC. | $126.07 | 2019-2025 | |
| Amgen INC. | $110.13 | 2019-2023 | Repatha |
| Actelion Pharmaceuticals US, INC. | $106.90 | 2019-2020 | |
| Lundbeck LLC | $69.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $60.46 | 2019-2020 | |
| Abbott Laboratories | $52.26 | 2019-2020 | |
| Amarin Pharma, INC. | $39.10 | 2019-2020 | |
| Astellas Pharma US INC | $39.05 | 2019-2020 | |
| Boston Scientific Corporation | $33.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.74 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.49 | 2024 | Verquvo |
| Portola Pharmaceuticals, LLC | $13.60 | 2019 | |
| Convatec INC. | $12.99 | 2019 | |
| Philips North America LLC | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.